Last reviewed · How we verify
PF-06342674 Dose D
At a glance
| Generic name | PF-06342674 Dose D |
|---|---|
| Sponsor | Pfizer |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
- Fatigue
- Hypoglycaemia
- Eye oedema
- Abdominal distension
- Diarrhoea
- Dry mouth
- Lip dry
- Vomiting
- Injection site erythema
- Injection site pain
- Injection site pruritus
- Peripheral swelling
Key clinical trials
- A Study To Assess The Safety Of PF-06342674 In Adults With Type 1 Diabetes (PHASE1)
- A Study To Assess The Safety Of PF-06342674 In Healthy Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PF-06342674 Dose D CI brief — competitive landscape report
- PF-06342674 Dose D updates RSS · CI watch RSS
- Pfizer portfolio CI